| COMMENTARY |
|
| Year : 2022 | Volume
: 17
| Issue : 4 | Page : 185-188 |
|
|
When single-inhaler triple therapy is a preferred option in asthma management?
Mohamed S Al-Moamary1, Riyad Al-Lehebi2, Majdy M Idrees3, Mohammed O Zeitouni4
1 Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
2 Pulmonary Section, Department of Medicine, King Fahad Medical City; Department of Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
3 Department of Medicine, Respiratory Division, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
4 Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Correspondence Address:
Prof. Mohamed S Al-Moamary
Department of Medicine, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/atm.atm_341_22
|
|
|
Asthma control is the main goal of management. Unfortunately, most asthma patients with moderate–severe asthma remain uncontrolled despite receiving standard treatment of inhaled corticosteroids (ICS) with long-acting β2 agonists (LABA). The addition of long-acting antimuscarinic agents (LAMA) has been shown to improve different aspects of asthma control, including symptoms, lung functions, and probably exacerbations. Such an option could be considered for low-T2 asthma phenotype. Umeclidinium and glycopyrronium bromide are other LAMA agents that have been recently made available in combination with ICS and LABA in single-inhaler triple therapy (SITT) devices. Here, we discuss the position of SITT as a new novel therapeutic option in asthma management and its clinical benefits, potential cost saving, and improved compliance.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
